Abattis Bioceuticals Corp. announced that it plans to launch a new line of products designed to alleviate pain and inflammation through its wholly owned subsidiary, Vergence Naturals Ltd. (Vergence). The launch is anticipated to take place on Cyber and the new product line will be the first of twelve products the Company hopes to launch over a 36-month period. Through Vergence, the Company plans a substantial direct response marketing campaign to increase awareness of the benefits of phytocannabinoid products from Vergence. The company is planning for campaign to launch on Cyber-Monday (November 26, 2018) and to include 25,200+ localized airings in every major U.S. city to a total of over 110 million households," stated Rob Abenante, President and CEO of Abattis. The Company will provide further details respecting the upcoming marketing campaign and product launch in subsequent news releases. The company has proud to have developed two products that safely reduce pain and modulate inflammation. Searches for pain remedies are among the top cannabis-related searches on Amazon.com and Google and confident that products will be well received by the growing number of consumers interested in cannabinoid-based therapies for pain and inflammation.